M A Weber

Summary

Country: USA

Publications

  1. ncbi The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme
    Michael Weber
    State University of New York Downstate College of Medicine, New York, USA
    J Hypertens Suppl 21:S37-46. 2003
  2. ncbi Cardiovascular protection for all individuals at high risk: evidence-based best practice
    George Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Clin Res Cardiol 97:713-25. 2008
  3. ncbi Association of Clinical Researchers and Educators a statement on relationships between physicians and industry
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, New York, 112013, USA
    Endocr Pract 18:1029-37. 2012
  4. ncbi Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    Lancet 381:537-45. 2013
  5. ncbi Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Hypertens 30:2213-22. 2012
  6. ncbi Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril
    Michael A Weber
    State University of New York, Downstate College of Medicine Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 14:588-92. 2012
  7. ncbi Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:322-9. 2003
  8. ncbi The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme
    Michael Weber
    State University of New York Downstate College of Medicine, New York, USA
    J Hypertens Suppl 21:S37-46. 2003
  9. ncbi Creating a combination antihypertensive regimen: what does the research show?
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 5:12-20. 2003
  10. ncbi An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements
    Michael A Weber
    SUNY Downstate Medical School, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 8:241-50; quiz 251-2. 2006

Collaborators

Detail Information

Publications91

  1. ncbi The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme
    Michael Weber
    State University of New York Downstate College of Medicine, New York, USA
    J Hypertens Suppl 21:S37-46. 2003
    ..This series of trials will characterize the end-organ protective effects of telmisartan in hypertensive patient populations at high risk of clinical events...
  2. ncbi Cardiovascular protection for all individuals at high risk: evidence-based best practice
    George Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Clin Res Cardiol 97:713-25. 2008
    ....
  3. ncbi Association of Clinical Researchers and Educators a statement on relationships between physicians and industry
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, New York, 112013, USA
    Endocr Pract 18:1029-37. 2012
    ....
  4. ncbi Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    Lancet 381:537-45. 2013
    ....
  5. ncbi Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Hypertens 30:2213-22. 2012
    ..To determine whether blood pressure (BP) control in hypertensive patients achieved with combination drug therapy provides the same cardiovascular benefits as with single-agent therapy...
  6. ncbi Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril
    Michael A Weber
    State University of New York, Downstate College of Medicine Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 14:588-92. 2012
    ..4 (P<.0001 vs combination), 14.4 ± 14.1 (P=.0470), and 16.1 ± 17.2 (P=.0704). Adverse event rates were similar in all groups. This study demonstrated the potential antihypertensive benefits of combining nebivolol with a RAS blocker...
  7. ncbi Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:322-9. 2003
    ..001 for each) with the increases in the GWBI scores. Controlling blood pressure appears to be an important element in improving subjective health perceptions of hypertensive patients...
  8. ncbi The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme
    Michael Weber
    State University of New York Downstate College of Medicine, New York, USA
    J Hypertens Suppl 21:S37-46. 2003
    ..This series of trials will characterize the end-organ protective effects of telmisartan in hypertensive patient populations at high risk of clinical events...
  9. ncbi Creating a combination antihypertensive regimen: what does the research show?
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 5:12-20. 2003
    ....
  10. ncbi An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements
    Michael A Weber
    SUNY Downstate Medical School, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 8:241-50; quiz 251-2. 2006
    ..A treatment algorithm based on the angiotensin receptor blocker, telmisartan, was confirmed by the blinded end point of ABPM as an efficacious alternative to other antihypertensive regimens in clinical practice...
  11. ncbi The JNC 7 report: challenges and dilemmas in writing guidelines
    M A Weber
    State University of New York Downstate College of Medicine, 450 Clarkson Avenue, Box 97, Brooklyn, NY 10103, USA
    J Clin Hypertens (Greenwich) 5:282-6. 2003
  12. ncbi Treatment of patients with hypertension and arthritis pain: new concepts
    Michael A Weber
    Downstate College of Medicine, State University of New York, Brooklyn, New York 10022, USA
    Am J Med 122:S16-22. 2009
    ..This article reviews some preliminary preclinical and clinical studies of key safety data of an investigational new NO-donating anti-inflammatory agent...
  13. ncbi Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Michael A Weber
    State University of New York Downstate, College of Medicine, New York 10118, USA
    J Renin Angiotensin Aldosterone Syst 4:62-73. 2003
    ..Some studies are also investigating whether more extensive RAAS blockade using a combination of an ARB and an ACE-I will offer even greater protection than either agent alone...
  14. ncbi Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes?
    Michael A Weber
    State University of New York, Health Sciences Center, New York, NY 10174, USA
    Blood Press Monit 8:215-22. 2003
    ....
  15. ncbi Hypertension treatment and implications of recent cardiovascular outcome trials
    Michael A Weber
    SUNY Downstate College of Medicine, New York, NY 10170, USA
    J Hypertens Suppl 24:S37-44. 2006
    ....
  16. ncbi Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, New York, USA
    Manag Care Interface 18:47-54. 2005
    ..Overall, angiotensin-II receptor blockers have a low incidence of side effects and provide improved QoL compared with standard therapies for patients with hypertension or heart failure...
  17. ncbi Controlled-release carvedilol in the treatment of essential hypertension
    Michael A Weber
    Department of Medicine, State University of New York Downstate College of Medicine, New York, New York 10170, USA
    Am J Cardiol 98:32L-38L. 2006
    ..We conclude that carvedilol CR is a very effective antihypertensive agent with clear dose-related peak blood pressure reduction and continuous 24-hour control...
  18. ncbi Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    J Clin Hypertens (Greenwich) 8:840-9. 2006
    ..Adverse events, including clinical chemistry values, were similar in the drug-treated and placebo groups. Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period...
  19. ncbi Angiotensin II receptor blockers in older patients
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY, USA
    Am J Geriatr Cardiol 13:197-205; quiz 206-7. 2004
    ....
  20. ncbi New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
    Michael A Weber
    State University of New York Downstate College of Medicine, New York, New York 10170, USA
    Am J Cardiol 100:45J-52J. 2007
    ....
  21. ncbi Beta-blockers in the treatment of hypertension: new data, new directions
    Michael A Weber
    State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA
    J Clin Hypertens (Greenwich) 10:234-8. 2008
  22. ncbi Calcium channel antagonists in the treatment of hypertension
    Michael A Weber
    SUNY Health Science Center at Brooklyn, Brooklyn, New York 11203 2098, USA
    Am J Cardiovasc Drugs 2:415-31. 2002
    ..Because of this important concept, calcium channel antagonists, like the other antihypertensive drug classes, are progressively being prescribed less often as monotherapy, but more typically as part of combination regimens...
  23. ncbi Managing the patient at risk for a second stroke
    Michael A Weber
    State University of New York Downstate College of Medicine, New York, USA
    J Hypertens Suppl 23:S41-7. 2005
    ....
  24. ncbi A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
    Michael A Weber
    State University of New York, Downstate College of Medicine, New York, NY 11203, USA
    Lancet 374:1423-31. 2009
    ..We investigated the blood-pressure-lowering effects of the new vasodilatory, selective endothelin type A antagonist, darusentan, in patients with treatment-resistant hypertension...
  25. ncbi Telmisartan in high-risk cardiovascular patients
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, New York, USA
    Am J Cardiol 105:36A-43A. 2010
    ..The choice of agent to be used in the long term could be based on other considerations, such as compliance and safety. Both cough and angioedema were higher with ramipril than telmisartan during the 56-month follow-up period in ONTARGET...
  26. ncbi Contrasting clinical properties and exercise responses in obese and lean hypertensive patients
    M A Weber
    State University of New York Downstate Medical Center, Brooklyn, USA
    J Am Coll Cardiol 37:169-74. 2001
    ....
  27. ncbi Rationalizing the treatment of hypertension
    M A Weber
    SUNY Health Science Center at Brooklyn, 11203, USA
    Am J Hypertens 14:3S-7S. 2001
    ....
  28. ncbi Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk
    Michael A Weber
    SUNY Downstate Medical College, 420 Lexington Avenue, Brooklyn, NY 10170, USA
    Blood Press 16:13-9. 2007
    ..It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease...
  29. ncbi Differing roles of body mass and the renin-angiotensin system in mediating the hypertension syndrome
    M A Weber
    The Brookdale University Hospital, SUNY Health Science Center, Brooklyn, NY 11212, USA
    Am J Nephrol 20:169-74. 2000
    ..This investigation has examined a possible role for the renin-angiotensin system as well as body mass and insulin values in mediating these cardiovascular and renal aspects of the hypertension syndrome...
  30. ncbi Introduction: the hemodynamic and vascular effects of angiotensin II: managing the consequences
    Michael A Weber
    State University of New York Health Science Center, Brooklyn 11203, USA
    Am J Hypertens 15:1S-2S. 2002
  31. ncbi The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
    Michael A Weber
    State University of New York Downstate Medical College, Brooklyn, New York, USA
    Am J Cardiol 89:27A-33A. 2002
    ..Inclusion of the telmisartan plus ramipril treatment arm will allow investigation of the potential advantages presented by combining an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist...
  32. ncbi Clinical implications of aldosterone blockade
    Michael A Weber
    SUNY Health Science Center at Brooklyn, Brooklyn, NY 11203, USA
    Am Heart J 144:S12-8. 2002
    ..The significant risk reduction provided by the addition of spironolactone to standard therapy in patients with severe heart failure has renewed interest in aldosterone blockade...
  33. ncbi Outcomes of treating hypertension in the elderly: a short commentary on current issues
    Michael A Weber
    Office of Scientific Affairs, SUNY Downstate College of Medicine, Brooklyn, NY 11203, USA
    Am J Geriatr Cardiol 12:14-8. 2003
    ..Even so, careful but effective control of blood pressure in elderly patients, including those over age 80, still remains a critical factor in preventing major cardiovascular events...
  34. ncbi Cardiovascular events during differing hypertension therapies in patients with diabetes
    Michael A Weber
    Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York 11203, USA
    J Am Coll Cardiol 56:77-85. 2010
    ..The aim of this study was to determine which combination therapy in patients with hypertension and diabetes most effectively decreases cardiovascular events...
  35. ncbi Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy
    M R Weir
    Department of Medicine, University of Maryland Medical System, Baltimore 21201, USA
    Am J Hypertens 9:854-9. 1996
    ..Adverse events, but not systolic or diastolic blood pressure reduction correlated directly with changes in quality of life...
  36. ncbi Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
    J L Pool
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Hypertens 11:462-70. 1998
    ..Withdrawal of irbesartan did not result in rebound hypertension or adverse events. Thus, once-daily irbesartan is both an effective and safe antihypertensive agent for the treatment of mild-to-moderate hypertension...
  37. ncbi Management of high-risk hypertensive patients with diabetes: potential role of angiotensin II receptor antagonists
    M A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 3:225-35. 2001
    ..c)2001 Le Jacq Communications, Inc...
  38. ncbi Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators
    M R Weir
    Department of Medicine, University of Maryland, Baltimore 21201 1595, USA
    Am J Hypertens 14:567-72. 2001
    ..Thus, candesartan cilexetil either alone or as add-on therapy was highly effective for the control of systolic or diastolic hypertension regardless of demographic background when used in typical clinical practice settings...
  39. ncbi When hypertension and diabetes coexist: strategies for cardiorenal protection
    M A Weber
    State University of New York Downstate College of Medicine, New York, USA
    Postgrad Med 108:12-8. 2000
    ..The data indicated the need for screening of hypertensive patients for diabetes and aggressive treatment to control hypertension...
  40. ncbi Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension
    M A Weber
    Department of Medicine, The Brookdale University Hospital and Medical Center, Brooklyn, New York 11212, USA
    Am J Hypertens 12:189S-194S. 1999
    ..Ongoing clinical trials will try to determine whether the effects of ARB can equal or even exceed the beneficial effects of ACE inhibitors on cardiovascular prognosis...
  41. ncbi Gender differences in vascular compliance in young, healthy subjects assessed by pulse contour analysis
    N Winer
    Department of Medicine, Division of Endocrinology, Diabetes, and Hypertension, SUNY Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 3:145-52. 2001
    ....
  42. ncbi Unsolved problems in treating hypertension: rationale for new approaches
    M A Weber
    Department of Medicine, The Brookdale University Hospital and Medical Center, Brooklyn, New York 11212, USA
    Am J Hypertens 11:145S-149S. 1998
    ..These approaches are also convenient and cost-effective. It remains to be learned whether newer drug combinations might exhibit additive cardiovascular protective actions...
  43. ncbi Translating data on antihypertensive drugs into clinical practice
    M A Weber
    Department of Medicine, The Brookdale University Hospital and Medical Center, Brooklyn, New York 11212, USA
    Am J Hypertens 11:89S-94S; discussion 95S-100S. 1998
    ....
  44. ncbi Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial
    G L Bakris
    Department of Medicine, Hypertension Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Kidney Int 72:879-85. 2007
    ..Our results suggest that patients with cardiovascular risk and relatively low albumin excretion rates in early-stage disease may only require monotherapy with renin-angiotensin-aldosterone blocking agents...
  45. ncbi Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
    Michael Weber
    Division of Cardiology, SUNY Downstate College of Medicine, New York, NY 10016, USA
    J Hypertens Suppl 27:S9-14. 2009
    ..Attributes such as effective blood pressure lowering, tolerability and convincing outcomes data mean that ARBs satisfy the requirements for first-line antihypertensive agents...
  46. ncbi Vasopeptidase inhibitors
    M A Weber
    Office of Scientific Affairs, SUNY Downstate Medical College, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 97, Brooklyn, NY 11203, USA
    Lancet 358:1525-32. 2001
    ....
  47. ncbi The effect of antihypertensive drugs on vascular compliance
    N Winer
    Division of Endocrinology, Diabetes, and Hypertension, SUNY Downstate Medical Center, Box 1205, 450 Clarkson Avenue, Brooklyn, NY 11203 2098, USA
    Curr Hypertens Rep 3:297-304. 2001
    ....
  48. ncbi Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines
    L Tobian
    American Society of Hypertension, New York, NY
    Am J Hypertens 7:859-72. 1994
    ..All seven experts who are deeply involved in the daily care of patients preferred drugs other than beta-blockers and diuretics (the Joint National Committee [JNC] choices) for first-line therapy of hypertension...
  49. ncbi The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial
    George Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago School of Medicine, Chicago, IL 60637, USA
    J Cardiometab Syndr 3:229-33. 2008
    ..8% of DM patients had blood pressure levels <130/80 mm Hg. ACCOMPLISH will provide valuable guidance on optimizing treatment strategies in hypertensive patients at high cardiovascular risk with and without DM...
  50. ncbi Pathophysiologic and therapeutic importance of tissue ACE: a consensus report
    Victor J Dzau
    Department of Medicine, Brigham Women s Hospital, Boston, MA 02115, USA
    Cardiovasc Drugs Ther 16:149-60. 2002
    ..Pharmacologic studies show that while ACE inhibitors may differ according to their binding affinity for tissue ACE the clinical significance remains to be determined...
  51. ncbi Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial
    George L Bakris
    University of Chicago, Department of Medicine, Hypertensive Disease Unit, Chicago, Ill, USA
    Hypertension 56:824-30. 2010
    ..The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies...
  52. ncbi The evolution of combination therapy in treating hypertension
    Michael A Weber
    J Clin Hypertens (Greenwich) 9:1-4. 2007
  53. ncbi Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
    Henry R Black
    New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 9:760-9. 2007
    ....
  54. ncbi Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma, 5850 W Wilshire Boulevard, Oklahoma City, OK 73132, USA
    Am J Hypertens 17:252-9. 2004
    ..The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with hydrochlorothiazide (HCTZ)...
  55. ncbi A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension
    Robert J Weiss
    Androscoggin Cardiology Associates, Auburn, ME 04210, USA
    J Clin Hypertens (Greenwich) 9:667-76. 2007
    ..002). The overall adverse event experience was similar in the nebivolol (46.1%) and placebo (40.7%) groups (P=.273). Once-daily nebivolol is an effective antihypertensive in mild to moderate hypertensive patients...
  56. ncbi ONTARGET: questions asked, questions answered
    Michael A Weber
    J Clin Hypertens (Greenwich) 10:427-30. 2008
  57. ncbi Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Blood Press 17:170-7. 2008
    ..We conclude that valsartan compared with amlodipine reduces the risk of developing diabetes mellitus, particularly in hypertensive patients with the highest susceptibility for development of diabetes...
  58. ncbi Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Rev Cardiovasc Med 9:96-105. 2008
    ..The use of carvedilol CR (once daily) may be preferable to a twice-daily regimen...
  59. ncbi Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy
    William C Cushman
    University of Tennessee College of Medicine and Veterans Affairs Medical Center, Memphis, TN, USA
    Am J Geriatr Cardiol 17:27-36. 2008
    ..Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy...
  60. ncbi Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass
    Joel M Neutel
    Orange County Heart Institute and Research Center, Orange, California, USA
    Am J Hypertens 17:37-42. 2004
    ..These findings indicate that appropriately selected combinations of antihypertensive drugs might have enhanced cardioprotective effects...
  61. ncbi The ALLHAT report: a case of information and misinformation
    Michael A Weber
    State University of New York, Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:9-13. 2003
  62. ncbi The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease
    Michael A Weber
    SUNY Health Science Center at Brooklyn, Brooklyn, NY, USA
    Rev Cardiovasc Med 3:183-91. 2002
    ....
  63. ncbi Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, Conn 06030-3940, USA. wwhite @nso1.uchc.edu
    Hypertension 41:1021-6. 2003
    ..Furthermore, eplerenone reduced microalbuminuria to a greater extent than amlodipine in this older patient group...
  64. ncbi Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors
    Franz H Messerli
    JAMA 289:2067-8; author reply 2069-70. 2003
  65. ncbi Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  66. ncbi Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial
    Thomas D Giles
    LSU School of Medicine, New Orleans, Louisiana, USA
    Am J Hypertens 16:460-6. 2003
    ....
  67. ncbi A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly
    Michael A Weber
    Division of Endocrinology, Diabetes, and Hypertension, SUNY Downstate Medical Center, Box 1205, 450 Clarkson Avenue, Brooklyn, NY 11203-2098, USA
    Curr Hypertens Rep 5:319-21. 2003
  68. ncbi ALLHAT--all hit or all miss? Key questions still remain
    Franz H Messerli
    Am J Cardiol 92:280-1. 2003
  69. ncbi Drug choice affects treatment compliance and blood pressure outcomes in elderly hypertensive patients
    Michael A Weber
    Am J Geriatr Cardiol 16:277-8. 2007
  70. ncbi The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension
    Domenic A Sica
    Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    J Clin Hypertens (Greenwich) 6:231-41. 2004
    ..Propranolol CR is an effective antihypertensive formulation that may reduce blood pressure during the morning period of maximum cardiovascular risk...
  71. ncbi Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy
    Elizabeth O Ofili
    Clinical Research Center, Morehouse School of Medicine, Atlanta, GA 30310, USA
    J Natl Med Assoc 98:618-26. 2006
    ..In conclusion, irbesartan/HCTZ treatment provided SBP/DBP goal attainment in approximately two-thirds of Caucasian, African-American and Hispanic/Latino patients with SBP uncontrolled on antihypertensive monotherapy...
  72. ncbi Is there more to life than blood pressure?
    Michael A Weber
    J Clin Hypertens (Greenwich) 7:149-51. 2005
  73. ncbi Feasibility of treating prehypertension with an angiotensin-receptor blocker
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI 48106, USA
    N Engl J Med 354:1685-97. 2006
    ..Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. We investigated whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension...
  74. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)...
  75. ncbi The role of the new beta-blockers in treating cardiovascular disease
    Michael A Weber
    Department of Medicine, State University of New York, Brooklyn, New York, USA
    Am J Hypertens 18:169S-176S. 2005
    ..Nebivolol is currently available in Europe for the management of hypertension and is expected to be available soon in the United States...
  76. ncbi Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    Am Heart J 151:176-84. 2006
    ..Therefore, we used ambulatory blood pressure monitoring (ABPM), an automated and objective measure of blood pressure (BP) to overcome these shortcomings in a large community-based trial...
  77. ncbi Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    J Clin Hypertens (Greenwich) 7:641-6; quiz 647-8. 2005
    ..This data supports the recommendation of the JNC 7 for the use of combination therapy in patients with stage 2 hypertension...
  78. ncbi Expanding the definition and classification of hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:505-12. 2005
    ..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
  79. ncbi Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
    ..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
  80. ncbi Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    Am J Geriatr Cardiol 15:142-50. 2006
    ..Adverse event rates were low and similar in all treatment groups. This study demonstrated that combination therapy is superior to monotherapy in older patients with stage 2 systolic hypertension and is well tolerated...
  81. ncbi Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
    Sverre E Kjeldsen
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Hypertens 24:1405-12. 2006
    ..8%) patients on valsartan and in 586 (11.8%) on amlodipine (OR 0.82, 95% CI 0.72-0.93, P = 0.0015). CONCLUSION: Compared with amlodipine, valsartan reduces the risk of developing diabetes mellitus in high-risk hypertensive patients...
  82. ncbi Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
    Michael A Weber
    State University of New York, Brooklyn, NY, USA
    Lancet 363:2049-51. 2004
    ....
  83. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  84. ncbi Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?
    Michael A Weber
    J Clin Hypertens (Greenwich) 6:425-7. 2004
  85. ncbi First-step use of fixed-dose combination treatment in stage 2 hypertensive patients: has the time come?
    Michael A Weber
    SUNY Downstate College of Medicine, New York, New York, USA
    J Clin Hypertens (Greenwich) 9:276-84. 2007
  86. ncbi Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension
    Michael A Weber
    SUNY Downstate College of Medicine, Brooklyn, NY, USA
    Rev Cardiovasc Med 5:148-55. 2004
    ....
  87. ncbi Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial
    Joel M Neutel
    Orange County Research Center, Tustin, California 92780, USA
    Am J Cardiovasc Drugs 4:335-41. 2004
    ..To evaluate the effectiveness and safety of perindopril in a subgroup of 3010 elderly (> or =65 years) hypertensive patients, who participated in a large US general practice-based community trial...
  88. ncbi Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Michael A Weber
    State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Rev Cardiovasc Med 7:45-54. 2006
    ....
  89. ncbi The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy
    Stevo Julius
    University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Dr, PO Box 322, Lobby M, Ann Arbor, MI 48106, USA
    Hypertension 48:385-91. 2006
    ..Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients...
  90. ncbi Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes
    James R Sowers
    University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
    J Clin Hypertens (Greenwich) 8:470-80. 2006
    ..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy...
  91. ncbi The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    J Clin Hypertens (Greenwich) 7:578-86. 2005
    ..Treatments were well tolerated. This irbesartan/HCTZ treatment regimen achieved SBP goals in more than 75% of patients uncontrolled on monotherapy...